Puneet Varma (Editor)


Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Routes of administration  Intravenous
PubChem CID  53234134
Molar mass  666.689 g/mol
CAS Number  689293-68-3
Formula  C23H30N12O8S2
Trade names  Zerbaxa (with tazobactam)
ATC code  J01DI54 (WHO) (combination with β-lactamase inhibitor)
Legal status  US: Approved January 2015

Ceftolozane is a 5th generation cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia. Ceftolozane is combined with the β-lactamase inhibitor tazobactam, which protects ceftolozane from degradation. Ceftolozane-tazobactam (trade name Zerbaxa) is indicated for the treatment of complicated urinary tract infections and complicated intra abdominal infections.

Spectrum of activity

The in vitro activity of ceftolozane–tazobactam has been examined in five surveillance studies of isolates from Europe and North America. In these studies, ceftolozane–tazobactam was notable for its activity against Pseudomonas aeruginosa, a moderately common cause of hospital-acquired infections that is commonly multi-drug resistant. Ninety percent of P. aeruginosa isolates were inhibited by a ceftolozane–tazobactam at a concentration of 4 μg/mL (MIC90), making it the most potent anti-pseudomonal antibiotic in clinical use.

In these same studies, ceftolozane–tazobactam exhibited MIC90 values of <1 μg/mL for Escherichia coli, Citrobacter koseri, Morganella morganii, Proteus mirabilis, Salmonella species, and Serratia marcescens. Somewhat poorer activity is observed for the Klebsiella and Enterobacter species, with the MIC90 for extended spectrum beta-lactamase (ESBL) expressing Klebsiella pneumonia being >32 μg/mL.


Ceftolozane Wikipedia

Similar Topics
Oh My God (2009 film)
Gabriela Berrios
Tomasz Miśkiewicz